Search clinical trials for: Tipifarnib;Zarnestra; R115777

Total 91 results

National Cancer Institute (NCI)

Completed

A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS)

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Adult Acute Myeloid Leukemia... and other conditions

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer

Breast Cancer

United Kingdom, United States, France, Russian Federation, Belgium, Netherlands
National Cancer Institute (NCI)

Completed

S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute... and other conditions

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older

Acute Myeloid Leukemia
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic... and other conditions

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia

United States
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Metastatic Malignant Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Kura Oncology, Inc.

Completed

Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia (CMML/AML)

Leukemia, Myelomonocytic, Chronic

United States
National Cancer Institute (NCI)

Completed

Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma

Untreated Childhood Brain Stem Glioma

United States
National Cancer Institute (NCI)

Terminated

Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia

T-cell Large Granular Lymphocyte Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Myelodysplastic Syndromes

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Cytopenia With Multilineage Dysplasia | Refractory Anemia With Excess Blasts in Transformation | Refractory Anemia...

United States
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Adult Acute Monoblastic Leukemia | Adult Acute Monocytic Leukemia | Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Adult Acute Myeloid Leukemia With Maturation | Adult Acute Myeloid Leukemia With Minimal... and other conditions

United States
National Cancer Institute (NCI)

Completed

Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma

United States
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic... and other conditions

United States
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders

Chronic Myelomonocytic Leukemia | Recurrent Disease | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable | Accelerated Phase of Disease | Chronic Phase of Disease

United States
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia in Remission | Myelodysplastic Syndrome With Excess Blasts | Adult Acute Monocytic Leukemia | Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 and other conditions

United States, Israel, Peru
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Splenic Marginal Zone Lymphoma | Anaplastic Large Cell Lymphoma | Recurrent Adult Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent... and other conditions

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma

Multiple Myeloma

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.

Terminated

A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma

Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer

United States
M.D. Anderson Cancer Center
Johnson & Johnson

Completed

Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme

Glioblastoma Multiforme

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.

Leukemia, Nonlymphocytic, Acute
Lymphoma Study Association

Terminated

Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma

Mantle Cell Lymphoma
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma

United States
National Cancer Institute (NCI)

Completed

R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

Neurofibroma, Plexiform | Neurofibromatosis Type I

United States, Germany
National Cancer Institute (NCI)

Completed

Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic... and other conditions

United States
National Cancer Institute (NCI)

Completed

Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation... and other conditions

United States
National Cancer Institute (NCI)

Completed

Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer

Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer

United States
Kura Oncology, Inc.

Completed

Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

Thyroid Cancer | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | HRAS Mutant Tumor | Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor

Spain, United States, Korea, Republic of, France, Belgium, Germany, Greece, Italy, Netherlands, United Kingdom
Spanish Lung Cancer Group

Terminated

Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS

Non Small Cell Lung Cancer

Spain
M.D. Anderson Cancer Center
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia

Leukemia, Myeloid, Chronic

United States
Emory University
Millennium Pharmaceuticals, Inc.; Ortho Biotech, Inc.

Completed

Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Canada
National Cancer Institute (NCI)

Completed

Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors

Solid Neoplasm

United States
Institut Claudius Regaud
Janssen-Cilag Ltd.

Completed

Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme

Glioblastoma Multiforme

France
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9923 R115777 in Treating Patients With Advanced Colorectal Cancer

Colorectal Cancer

United States
National Cancer Institute (NCI)

Completed

Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma

United States
Kura Oncology, Inc.

Completed

Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy. (PTCL)

Relapsed or Refractory Peripheral T-Cell Lymphoma

United States, Spain, Korea, Republic of
Kura Oncology, Inc.

Terminated

Tipifarnib in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
National Cancer Institute (NCI)

Completed

Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer

Advanced Malignant Neoplasm

United States
National Cancer Institute (NCI)

Completed

Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase

Recurrent Adult Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Disease | Recurrent Adult Acute Lymphoblastic Leukemia | Adult Acute Monoblastic Leukemia | Adult Acute Monocytic Leukemia | Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Adult Acute Myeloid... and other conditions

United States
National Cancer Institute (NCI)

Completed

Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma

United States
National Cancer Institute (NCI)

Completed

Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Male Breast Carcinoma | Inflammatory Breast Carcinoma | Adult Solid Neoplasm

United States
National Cancer Institute (NCI)

Completed

Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia

Chronic Myelomonocytic Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer

Adenocarcinoma of the Pancreas | Stage III Pancreatic Cancer | Stage II Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma

United States
National Center for Research Resources (NCRR)

Unknown

Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)

Cancer

United States

Search clinical trials for: Tipifarnib;Zarnestra; R115777

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations